Safety of Estrogens in Lupus: Birth Control Pills
Launched by NYU LANGONE HEALTH · Nov 3, 1999
Trial Information
Current as of May 11, 2025
Completed
Keywords
ClinConnect Summary
This study tests the effect of exogenous female hormones on disease activity and severity in women with systemic lupus erythematosus (SLE). Physicians generally do not prescribe oral contraceptives (OCs) to women with lupus because of the widely held view that these drugs can activate SLE. This practice is based on the greater incidence of SLE in women than in men, biologic abnormalities of estrogen metabolism, murine models of lupus, several anecdotes of patients having disease flares while receiving exogenous hormones, and a single retrospective study in patients with preexisting renal di...
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Female
- • Unequivocal diagnosis of SLE
- • Inactive disease or be stable on 0.5 mg/kg/day or less of predisone
- • Must be between 18 and 39 years old if non-smoker
- • Must be between 18 and 35 years old if smoker
- Exclusion Criteria:
- • Blood pressure \>145/95 on three occasions
- • Deep vein, arterial thrombosis or pulmonary embolus
- • GPL \>40; MPL \>40; APL \>50; dRVVT \>37 sec
- • APL antibody syndrome ever
- • Gynecologic or breast cancer
- • Hepatic dysfunction or liver tumors
- • Diabetes mellitus (NOT due to steroids) with vascular disease
- • Congenital hyperlipidemia
- • Complicated migraine
- • Severe disease activity (SLEDAI \>12)
- • Increase in SLEDAI \>2 points in 3 months
- • Unexplained vaginal bleeding
- • Use of estrogen (OCP) for \>1 month at any time after SLE diagnosis
- • Present pregnancy
- • Angina or MI due to APS
- • Age \>35 yrs. for smokers; \>39 yrs. for nonsmokers
About Nyu Langone Health
NYU Langone Health is a premier academic medical center located in New York City, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. As a leading sponsor of clinical trials, NYU Langone Health integrates cutting-edge scientific inquiry with patient-centered care, striving to develop new therapies and improve health outcomes across a wide range of medical conditions. The institution is dedicated to fostering collaboration among researchers, clinicians, and patients, ensuring rigorous adherence to ethical standards and regulatory guidelines in all clinical research initiatives. By leveraging its extensive resources and expertise, NYU Langone Health aims to contribute significantly to the advancement of medical knowledge and the enhancement of patient care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Los Angeles, California, United States
Chicago, Illinois, United States
New York, New York, United States
Chapel Hill, North Carolina, United States
Oklahoma City, Oklahoma, United States
Philadelphia, Pennsylvania, United States
Pittsburgh, Pennsylvania, United States
Houston, Texas, United States
Milwaukee, Wisconsin, United States
Shreveport, Louisiana, United States
Baltimore, Maryland, United States
Ann Arbor, Michigan, United States
Bronx, New York, United States
New York, New York, United States
Richmond, Virginia, United States
Patients applied
Trial Officials
Jill P. Buyon, MD
Principal Investigator
Hospital for Joint Diseases
Michelle Petri, MD
Study Director
Johns Hopkins University Hospital, Dept. of Rheumatology
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials